cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Delayed NYSE Other stock markets 20:12:33 07/07/2026 +03			5-day change	1st Jan Change
0.7350 ^USD	+3.23%		+9.93%	-45.20%

05:07pm	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026

05-15

More transcripts

Analysts' recommendations: cbdMD, Inc.

05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CBDMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	01/03/2017
William Raines BRD	Director/Board Member	66	19/04/2019
Scott Stephen CHM	Chairman	60	03/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/07/26	$0.7350	+3.23%	213,927
06/07/26	$0.7120	+3.94%	87,118
02/07/26	$0.6850	+0.75%	72,420
01/07/26	$0.6799	+1.03%	106,658
30/06/26	$0.6730	-3.86%	122,972

Delayed Quote NYSE

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7120USD

Average target price

2.000USD

Spread / Average Target

+180.90%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	7.47M 6.54M 6.03M 5.59M 10.61M 709M 10.78M 72.28M 28.11M 350M 28.06M 27.45M 1.21B	P/E 2026 *	-3.75x	P/E 2027 *	-10.2x
Enterprise Value	7.47M 6.54M 6.03M 5.59M 10.61M 709M 10.78M 72.28M 28.11M 350M 28.06M 27.45M 1.21B	EV / Sales 2026 *	0.34x	EV / Sales 2027 *	0.32x
Free-Float	89.32%	Yield 2026 *	-	Yield 2027 *	-

05:07pm	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-15	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-15	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
04-01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI
02-18	CbdMD, Inc., Q1 2026 Earnings Call, Feb 17, 2026
02-18	CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-03	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI
01-29	CbdMD, Inc. Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways	CI
01-14	cbdMD announces strategic acquisition of Bluebird Botanicals	RE

03:31pm	CbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination	PR
07-01	Oasis Launches Hemp-Derived Mixer	PR
06-25	CbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products	PR
06-16	CbdMD Appoints Wade Brown Chief Marketing Officer	PR
05-14	CbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum	PR

1 day	+2.53%
1 week	+9.93%
Current month	+9.93%
1 month	+2.75%
3 months	+3.47%
6 months	-32.75%
Current year	-45.20%

1 week	0.66	0.74
1 month	0.65	0.74
Current year	0.63	1.34
1 year	0.47	2.56
3 years	0.47	13.84
5 years	0.47	1,087.2
10 years	0.47	2,606.4

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news : cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
04-14	Sibyl Swift	Free	Chief Technology Officer	1,572	0.0150%
04-14	Bakari Sellers	Free	Director	1,572	0.0150%
04-14	Jeffrey Porter	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+3.23%	+9.93%	-14.29%	-93.71%	7.47M
ELI LILLY AND COMPANY	+2.63%	+2.53%	+59.12%	+172.02%	1,070B
JOHNSON & JOHNSON	+2.86%	+5.23%	+72.11%	+67.81%	624B
ABBVIE INC.	+0.18%	+1.58%	+36.23%	+88.64%	450B
ROCHE HOLDING AG	+2.14%	-2.07%	+27.62%	+22.57%	328B
ASTRAZENECA PLC	+1.87%	+1.87%	+40.58%	+42.08%	292B
NOVARTIS AG	+1.36%	+0.17%	+29.90%	+49.33%	284B
NOVO NORDISK A/S	+1.98%	+4.08%	-25.78%	-39.02%	217B
AMGEN INC.	+0.34%	+1.58%	+25.57%	+68.24%	198B
GILEAD SCIENCES, INC.	+3.63%	+6.59%	+20.48%	+80.96%	161B
Average	+1.96%	+1.05%	+27.15%	+45.89%	362.44B
Weighted average by Cap.	+2.04%	+0.70%	+43.25%	+87.76%

	2026 *	2027 *
Net sales	22.15M 19.39M 17.87M 16.56M 31.44M 2.1B 31.94M 214M 83.31M 1.04B 83.17M 81.37M 3.59B	23.26M 20.36M 18.76M 17.39M 33.01M 2.21B 33.54M 225M 87.48M 1.09B 87.33M 85.44M 3.77B
Net income	-1.9M -1.66M -1.53M -1.42M -2.7M -181M -2.74M -18.39M -7.15M -89.09M -7.14M -6.99M -308M	-902K -789K -727K -674K -1.28M -85.61M -1.3M -8.72M -3.39M -42.25M -3.39M -3.31M -146M
Net Debt	-	-